Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

[1]  Y. Sekido,et al.  E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells , 2017, Oncogene.

[2]  Huamin Wang,et al.  Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype , 2015, Laboratory Investigation.

[3]  P. Timpson,et al.  FAK signaling in human cancer as a target for therapeutics. , 2015, Pharmacology & therapeutics.

[4]  J. Yang,et al.  213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors , 2014 .

[5]  Jingting Jiang,et al.  Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival. , 2014, International journal of clinical and experimental pathology.

[6]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[7]  Andrea I. McClatchey,et al.  Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship , 2014, Science Translational Medicine.

[8]  W. Sommergruber,et al.  IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction , 2014, Oncogene.

[9]  S. Yamada,et al.  Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. , 2013, Surgery.

[10]  I. Wistuba,et al.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. , 2013, Cancer discovery.

[11]  R. Plummer,et al.  610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma , 2012 .

[12]  A. Razak,et al.  396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors , 2012 .

[13]  Li Ma,et al.  MicroRNA control of epithelial–mesenchymal transition and metastasis , 2012, Cancer and Metastasis Reviews.

[14]  M. Schleicher,et al.  Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer. , 2011 .

[15]  R. Hruban,et al.  Loss of E-Cadherin Expression and Outcome among Patients with Resectable Pancreatic Adenocarcinomas , 2011, Modern Pathology.

[16]  Michael D Schaller,et al.  Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions , 2010, Journal of Cell Science.

[17]  Jörg Rahnenführer,et al.  Robert Gentleman, Vincent Carey, Wolfgang Huber, Rafael Irizarry, Sandrine Dudoit (2005): Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2009 .

[18]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[19]  R. Gentleman.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2006 .

[20]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[21]  Malorye A. Branca,et al.  Multi-kinase inhibitors create buzz at ASCO , 2005, Nature Biotechnology.

[22]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[23]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .